Stimulant effects of 3,4-methylenedioxymethamphetamine in the nucleus accumbens of rat.
European Journal of Pharmacology April 7, 1992 DOI: 10.1016/0014-2999(92)90094-k (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Rats |
| Interventions | S-amphetamine MBDB |
| Topics | MDMA |
| Citations | 35 |
| Key findings | S-MDMA injected into the nucleus accumbens produces locomotor hyperactivity that is not blocked by fluoxetine, indicating its action there is via catecholamine release rather than serotonin release. |
Abstract
This study examined the behavioral effects in rats of intracerebral administration of S(+)-3,4-methylenedioxymethamphetamine (S-MDMA) using an automated holeboard and open-field apparatus. Administration of S-MDMA into the nucleus accumbens septi produced locomotor hyperactivity. Although the stimulant effects of S-MDMA administered systemically are antagonized by fluoxetine pretreatment, the activating effects of S-MDMA administered into the nucleus accumbens were not antagonized by fluoxetine. A similar increase in locomotor activity was observed after S-amphetamine administration into the nucleus accumbens. In contrast, the selective 5-HT-releasing drug and S-MDMA congener N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB) produces MDMA-like locomotor hyperactivity when administered systemically but did not alter locomotor activity when injected into the nucleus accumbens. These data indicate that S-MDMA actions in the nucleus accumbens are pharmacologically distinct from the primary effects of systemically administered S-MDMA. Behavioral effects of S-MDMA in the nucleus accumbens may result from the catecholamine-releasing properties that S-MDMA shares with S-amphetamine and not via the 5-HT-releasing properties that it shares with MBDB.